XML 94 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Company information (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 6 Months Ended 8 Months Ended 10 Months Ended 12 Months Ended
Jun. 15, 2021
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2021
EUR (€)
May 31, 2021
USD ($)
study
Mar. 31, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2021
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3                      
Disclosure Of Information Related To The Company [Line Items]                      
Upfront payment       $ 4,000 $ 2,500   € 5.4   $ 6,500 $ 6,500 € 5.4
Milestone payment upon receipt of clinical study reports         1,000 $ 1,000          
Milestone payment upon second regulatory approval         $ 5,000 $ 5,000          
Royalties agreement, period         10 years 10 years          
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | Maximum                      
Disclosure Of Information Related To The Company [Line Items]                      
Onerous contracts provision         $ 12,500 $ 12,500          
LianBio, NBTXR3                      
Disclosure Of Information Related To The Company [Line Items]                      
Number of global registrational studies supported | study       5              
Upfront payment received $ 20,000 $ 20,000 € 16.5         $ 20,000      
LianBio, NBTXR3 | Maximum                      
Disclosure Of Information Related To The Company [Line Items]                      
Potential development and commercial milestones payments       $ 220,000       $ 220,000 $ 220,000 $ 220,000